European Heart Journal Advance Access published online on September 5, 2006
European Heart Journal, doi:10.1093/eurheartj/ehl220
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 The TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
* To whom correspondence should be addressed. Aims The impact of intensive lipid lowering therapy with statins in acute coronary syndrome (ACS) patients with diabetes mellitus (DM) is not well characterized. Methods and results We explored this question in data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT) TIMI 22 trial, which tested standard (pravastatin 40 mg) vs. intensive (atorvastatin 80 mg) statin therapy among patients treated early in the post-ACS period. We compared outcomes between patients with DM (identified by history, fasting plasma glucose Conclusion In ACS patients with DM, intensive statin therapy reduces acute cardiac events as it does in those without DM, with 55 vs. 40 events prevented per 1000 patients treated. However, our data highlight the need for additional strategies in this high-risk group.
Received February 12, 2006
Revised August 11, 2006
Accepted August 17, 2006
Clinical research
Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial
Shaheeda Ahmed 1, Christopher P. Cannon 1 *, Sabina A. Murphy 1, and Eugene Braunwald 1
Christopher P. Cannon, E-mail: cpcannon{at}partners.org
Abstract 
126 mg/dL or haemoglobin A1C > 7%; n = 978) against those without DM (n = 3184). The rate of acute cardiac events (death, myocardial infarction, and unstable angina requiring rehospitalization) was much higher in patients with DM, but was reduced with intensive vs. standard therapy similarly in diabetic (21.1 vs. 26.6%, HR=0.75, P = 0.03) and non-diabetic patients (14.0 vs. 18.0%, HR=0.76, P = 0.002); P-interaction=0.97. Despite intensive therapy, the majority of diabetics (62%) did not reach the dual goal of LDL-C < 70 mg/dL and high-sensitivity C-reactive protein <2 mg/L.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. M. Cubbon, C. P. Gale, A. Rajwani, A. Abbas, C. Morrell, R. Das, J. H. Barth, P. J. Grant, M. T. Kearney, and A. S. Hall Aspirin and Mortality in Patients With Diabetes Sustaining Acute Coronary Syndrome Diabetes Care, February 1, 2008; 31(2): 363 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Giugliano and E. Braunwald The Year in Non ST-Segment Elevation Acute Coronary Syndrome J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1386 - 1395. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Behfar and A. Terzic Cardioprotective repair through stem cell-based cardiopoiesis J Appl Physiol, October 1, 2007; 103(4): 1438 - 1440. [Abstract] [Full Text] [PDF]
|
|